Literature DB >> 2675999

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

G Mathé1, Y Kidani, M Segiguchi, M Eriguchi, G Fredj, G Peytavin, J L Misset, S Brienza, F de Vassals, E Chenu.   

Abstract

A new platinum complex, oxalatoplatin or l-OHP, which, at the same metal dose in experimental tests is as efficient as cisplatin, and is more so at a lower metal dose than carboplatin; which is as efficient in human tumors of the testis and ovary as these other analogs, and more so in melanoma and breast cancer; which is not nephrotoxic, cardiotoxic or mutagenic, and hardly hematotoxic and neurotoxic, is described and compared with the above-mentioned platinum complexes. Combined with 5Fu, it induces a high number of remissions in colorectal cancer, and has brought about cures in inoperable gastric cancers. Combined with carboplatin, it has resulted in a high proportion of cures in L1210-carrying mice, which no other two-by-two combination of these complexes has achieved.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2675999     DOI: 10.1016/0753-3322(89)90003-6

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  35 in total

Review 1.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.

Authors:  Apostolia Maria Tsimberidou; Michael J Keating; Elias J Jabbour; Farhad Ravandi-Kashani; Susan O'Brien; Elihu Estey; Neby Bekele; William K Plunkett; Hagop Kantarjian; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-03

Review 3.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

4.  Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy.

Authors:  S J Valle; N A Alzahrani; W Liauw; P H Sugarbaker; A Bhatt; D L Morris
Journal:  Indian J Surg Oncol       Date:  2016-02-05

5.  Combination chemotherapy of oxaliplatin, 5-fluorouracil and low dose leucovorin in patients with advanced colorectal cancer.

Authors:  Yoon Mi Shin; Hae Suk Han; Seong Woo Lim; Byung Chul Kim; Kyung Suck Cheoi; Young Ook Eum; Seung Taek Kim; Ki Hyeong Lee
Journal:  Cancer Res Treat       Date:  2005-10-31       Impact factor: 4.679

6.  Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.

Authors:  Carmen Plasencia; Albert Abad; Eva Martinez-Balibrea; Miquel Taron
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

Review 7.  New cisplatin analogues in development. A review.

Authors:  Raymond B Weiss; Michaele C Christian
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 8.  First-line treatment strategies to improve survival in patients with advanced colorectal cancer.

Authors:  Sharlene Gill; Richard M Goldberg
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.

Authors:  Dene Simpson; Christopher Dunn; Monique Curran; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Expression of Na,K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin.

Authors:  Ramakumar Tummala; Daniel Wolle; Sonali P Barwe; Valerie B Sampson; Ayyappan K Rajasekaran; Lakshmi Pendyala
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-26       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.